What does this company do?
Influx Healthtech Limited is engaged in the manufacturing of nutraceutical products. The company manufactures and supplies nutraceutical formulations to customers in the nutraceutical industry.
Issue parameters, key dates and structure.
P&L, Balance Sheet and Cash Flow — all figures in ₹ Crores.
| Particulars (₹ Cr) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue from Operations | 10485.36 | 9996.51 | 7605.65 |
| EBITDA | 2057.14 | 1695.56 | 1072.34 |
| EBITDA Margin | 19.6% | 17.0% | 14.1% |
| Depreciation & Amortisation | 282.45 | 185.43 | 93.74 |
| EBIT | 1775.46 | 1510.13 | 978.60 |
| Finance Costs (Interest) | 0.09 | 21.94 | 4.97 |
| PBT (Profit Before Tax) | 1787.91 | 1493.28 | 973.63 |
| Tax | 451.31 | 380.48 | 254.00 |
| PAT (Net Profit) | 1336.60 | 1112.80 | 719.63 |
| PAT Margin | 12.7% | 11.1% | 9.5% |
| EPS — Basic (₹) | 7.36 | 6.13 | 3.96 |
| EPS — Diluted (₹) | 7.36 | 6.13 | 3.96 |
All figures in ₹ Crores (INR). Data sourced from DRHP/RHP.
Valuation and profitability metrics at the IPO price.
Internal strengths & weaknesses; external opportunities & threats.
Strong revenue growth trajectory
Healthy profit margins
Low financial leverage
Experienced promoter management
Concentration in nutraceutical sector
SME listing may impact liquidity
High promoter shareholding dilution post-IPO
Growing nutraceutical market in India
Expansion of product portfolio
Geographic expansion
Strategic partnerships
Customer concentration risk
Regulatory changes in nutraceutical sector
Competition from larger players
Raw material price volatility
Key advantages highlighted in the DRHP.
Strong revenue growth with CAGR of approximately 17.8% over FY2023-FY2025
Healthy profitability with PAT margin of 12.7% in FY2025
Low debt levels with total borrowings of only ₹21.92 crores as of March 31, 2025
Experienced promoter management with established industry presence
Growing EBITDA margins demonstrating operational efficiency
Strategic position in growing nutraceutical sector
Pre & post-IPO shareholding pattern. Click a promoter card to learn more.
Material risk factors to consider before applying.
Dependence on nutraceutical industry for majority of revenue
Risk of loss of key customers
Competition from established players in nutraceutical manufacturing
Regulatory changes affecting nutraceutical sector
Liquidity risks for SME platform listed shares
Dependence on promoter-led management
Influx Healthtech Limited is a nutraceutical manufacturer with strong revenue growth of 17.8% CAGR (FY2023-FY2025) and healthy PAT margins of 12.7%. The company maintains a lean balance sheet with minimal debt (₹21.92 Cr) and generates robust cash flows. Trading at a P/E of 13.04x on FY2025 earnings, the valuation appears reasonable for an SME-listed healthcare company with consistent profitability and growth trajectory. Key risks include customer concentration in the nutraceutical sector and SME platform liquidity constraints, but strong fundamentals and low financial risk support a positive investment outlook for listing gains.
⚠️ This is not investment advice. CheckIPO provides information for educational purposes only. Always consult a SEBI-registered financial advisor before investing.
Key milestones from opening to listing.
Institutions managing the issue and handling allotment.
Registered information and contact details.